Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label study of azilsartan (TAK-536) in pediatric hypertension
jRCT2080223205Phase 3Completed
- Sponsor
- Takeda
- Start
- May 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of azilsartan in hypertension (HTN) (2 cohorts), sponsored by Takeda. Primary endpoints: Safety of azilsartan in pediatric hypertension, Efficacy: blood pressure reduction and 1 more. Started May 2016; status: completed.
02
Drugs
azilsartan
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on jRCT2080223205.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223205.